Pharma firm Advanz fined after thyroid drug price hike of 6,000%

Competition watchdog found company’s ‘excessive and unfair’ prices cost NHS almost £30m extra over 10 years

The UK’s competition watchdog has imposed fines of more than £100m on the pharmaceutical company Advanz and its former private equity owners after it was found to have inflated the price of its thyroid tablets by up to 6,000%.

An investigation by the Competition and Markets Authority (CMA) found that the private-equity backed pharmaceutical company charged “excessive and unfair prices” for liothyronine tablets, which are used to treat thyroid hormone deficiency.

Advanz took advantage of limited competition in the market from 2007 to bring in sustained price hikes for the drug, often used by patients with depression and fatigue, of more than 6,000% in the space of 10 years, according to the investigation.

The CMA said that between 2007 and 2017, the price paid by the NHS for liothyronine tablets rose from £4.46 to £258.19, a rise of almost 6,000%, while production costs remained broadly stable.

Repeated price increases led NHS spending on the tablets to soar from £600,000 in 2006, before the price increase strategy was implemented, to more than £2.3m by 2009 and as much as £30m by 2016. The tablets were placed on the NHS “drop list” in July 2015, which meant GPs could no longer prescribe them, causing many people who relied on the drug to face the prospect of having their treatment stopped or having to purchase it at their own expense.

Patients told the Guardian they were left with no option but to pay private doctors for prescriptions, and forced to hunt for cheaper tablets over the internet, buying the medication from online pharmacies and foreign suppliers without knowing whether the tablets being sold were genuine.

The CMA said this was “particularly concerning” because many patients do not respond well to the main treatment for hypothyroidism – levothyroxine tablets – and rely on liothyronine to treat their extreme fatigue and depression.

Advanz will be fined almost £41m, and two of its former private equity owners – Hg Capital and Cinven – will pay penalties of £8.6m and £51.9m respectively.

Dr Andrea Coscelli, the CMA’s chief executive, said: “Advanz’s decision to ratchet up the price of liothyronine tablets and impose excessive and unfair prices for over eight years came at a huge cost to the NHS, and ultimately to UK taxpayers.

“But that wasn’t all. It also meant that people dealing with depression and extreme fatigue, as a result of their thyroid conditions, were told they could not continue to receive the most effective treatment for them due its increased price.”

He said the CMA’s £100m fine and other work in the pharmaceutical sector would send “a clear message that breaking the law has serious consequences”.

The CMA imposed fines of more than £260m two weeks ago on pharmaceutical companies that had overcharged the NHS for almost a decade for hydrocortisone tablets, which tens of thousands of people rely on to treat adrenal insufficiency.

Its latest intervention against Advanz follows a five-year investigation that began in October 2016 and involved multiple companies.

The company was originally two separate entities, Mercury Pharma Group and Amdipharm.

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

London-based private equity group Hg Capital bought Mercury for £179m in 2009 and sold it to fellow buyout house Cinven for £465m in 2012. Cinven had bought family-owned niche pharmaceuticals business Amdipharm that same year, for £367m, and subsequently merged the two businesses.

In 2015, Cinven sold the combined entity to Concordia Healthcare, a Canadian company listed on the Toronto stock exchange, in a £2.3bn deal. In 2018, a year after the CMA first accused the company of abusing its position, Concordia changed its name to Advanz Pharma.

It later de-listed from the stock exchange, underwent a financial restructuring, and was bought in 2021 by Copenhagen-based Nordic Capital for £605m.

• This article was amended on 30 July 2021. An earlier version misspelled Amdipharm as “Adipharm” and omitted the byline of Rob Davies.


Jillian Ambrose and Rob Davies

The GuardianTramp

Related Content

Article image
Drug firm that hiked prices by 6,000% paid shareholders £400m
Advanz Pharma and former private equity owners were fined £100m by markets watchdog

Rob Davies

30, Jul, 2021 @2:17 PM

Article image
Drug firm Concordia overcharged NHS with 6,000% price rise, says watchdog
CMA accuses Canadian firm of overcharging by £100m on thyroid drug with price per pack rising from £4.46 to £258 in 10 years

Julia Kollewe

21, Nov, 2017 @1:50 PM

Article image
UK pharma firms accused of illegal deals to hike price of life-saving drug
Actavis charged NHS 80% more for hydrocortisone tablets after incentivising rival Concordia not to launch its own version, watchdog claims

Angela Monaghan

03, Mar, 2017 @12:54 PM

Article image
Pfizer fined record £84.2m over NHS overcharging
Competition regulator says price of anti-epilepsy drug was increased by up to 2,600%

Angela Monaghan

07, Dec, 2016 @8:01 AM

Article image
Price gouging fine for Advanz is a rare story that is becoming common | Phillip Inman
Competition and Markets Authority is working on a string of cases involving the NHS being overcharged for drugs

Phillip Inman

29, Jul, 2021 @6:34 PM

Article image
Pain aggravation: the human cost of medicine price hikes
After Advanz’s £100m fine over the price of its thyroid tablets, two people recount the difficulty of obtaining medication

Rachel Hall

30, Jul, 2021 @5:00 AM

Article image
Pfizer and Flynn accused of overcharging NHS for anti-epilepsy drugs
Competition regulator the CMA alleges drugs firms abused dominant position with unfairly high prices

Jillian Ambrose

05, Aug, 2021 @3:48 PM

Article image
Drug firm Novartis fears no-deal Brexit could put patients at risk
Swiss company is stockpiling amid concerns about the supply and safety of medicines

Jasper Jolly

25, Jan, 2019 @7:06 PM

Article image
Philip Morris International makes £1bn offer for UK pharma firm Vectura
Tobacco giant strikes deal for British firm developing pioneering inhaled treatment for Covid-19

Mark Sweney

09, Jul, 2021 @8:16 AM

Article image
UK drug companies fined £260m for inflating prices for NHS
Watchdog issues warning after abuses that included paying would-be rivals to stay out of the market

Jillian Ambrose

15, Jul, 2021 @9:25 AM